TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05446987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Position change and back massage
Description: Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early ambulation
Description: The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
Study: NCT04567472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping Ease Anxiety and Depression following Stroke
Description: HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
Study: NCT04455035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Retrospective Group(Control)
Description: The control group for this study will be obtained from a retrospective chart review of electronic health records of patients with incomplete cleft lip who underwent surgery without any presurgical interventions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prospective Group
Description: The study population for the prospective aspect will include recruited newborns with untreated unilateral incomplete cleft lip.~DynaCleft® + Nasal Elevator therapy will be discussed with parent(s) as a presurgical orthopedic option while awaiting primary cleft lip surgical repair that typically occurs between the ages of 3 to 6 months.Study duration will be up to three months of presurgical intervention.Photographs are to be taken at initial visit prior to presurgical intervention and later at completion of the DynaCleft® therapy immediately prior to lip surgery. Angles to be pictured are to include the standard anterior-posterior, profile, and worms-eye view.~Linear measurements will be obtained with a ruler and registered in millimeters. A goniometer will be used to measure angles.
Study: NCT04636255

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Physical Characteristics
Description: Body Weight, Height

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Characteristics
Description: Body Weight, Height

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Assessment of Heart rate variability
Description: Holter 24h

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of Heart rate variability
Description: Holter 24h

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Blood Pressure and Cardiac Autonomic Control
Description: Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Pressure and Cardiac Autonomic Control
Description: Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Evaluation of Baroreflex Control
Description: The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of Baroreflex Control
Description: The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Cardiac Function and Structure
Description: Echocardiogram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Function and Structure
Description: Echocardiogram

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Assessment of Coronary Anatomy and Calcium Score
Description: Angiotomography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of Coronary Anatomy and Calcium Score
Description: Angiotomography

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Blood Assessments
Description: Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Assessments
Description: Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).
Study: NCT03084107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The elderly participated in the application of smart devices and requested to complete technology acceptance model (TAM) questionnaires for these devices.
Study: NCT02767466

Intervention type: PROCEDURE
Intervention: Physical therapy and robotic assisted gait training
Study: NCT05101889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Impact®
Description: 3 ready-to-drink bottles/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact®
Description: 3 ready-to-drink bottles/day
Study: NCT03618160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
Study: NCT02801513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Training
Description: Brief mindfulness training comprising of three weekly individual sessions and daily guided meditation home practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resting Control Training
Description: Brief resting control training comprising of three weekly individual sessions and daily home practice consisting of resting periods
Study: NCT03726047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will complete 5 minutes of exercise on an ergometer to examine the effects of exercise on retention of a newly learned walking pattern.
Study: NCT04636255

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Physical Capacity
Description: Cardiopulmonary Exercise Test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Capacity
Description: Cardiopulmonary Exercise Test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Aerobic exercise: 48 sessions of 60 minutes: 5 minutes of warm-up, 40 minutes of exercise. Resistance exercise: 10 minutes of exercise and 5 minutes of recovery.
Study: NCT03321968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Influenza Vaccine
Description: Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Influenza Vaccine
Description: Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Influenza Vaccine
Description: Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine
Study: NCT02138487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liberal postoperative activity
Description: Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restricted postoperative activity
Description: Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
Study: NCT02337608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: GLPG1205 daily dosing in the morning for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo daily dosing in the morning daily for 12 weeks
Study: NCT02804594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: 1250 mg of N- acetyl cysteine taken three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo taken three times daily
Study: NCT03425201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib plus Cabozantinib
Description: Non-randomized trial will comprise 2 stages. A dose escalation phase will characterize the safety, tolerability, DLTs and MTD, of oral niraparib plus cabozantinib in patients with urothelial or renal cell carcinoma. Subsequently, the phase II will further evaluate the safety and antitumor activity of this combination in patients with urothelial carcinoma.
Study: NCT03226808

Intervention type: DEVICE
Group type: OTHER
Intervention: Vivacit-E Liner
Description: All subjects enrolled will receive the Vivacit-E liner.
Study: NCT00098514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talotrexin ammonium
Study: NCT03748680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy
Description: Six months of adjuvant combination chemotherapy with Capox (or FOLFOX) Patients will receive adjuvant chemotherapy with eight cycles of CAPOX (oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.~(Patients with an ileostomy are only eligible for FOLFOX and will be treated with 12 cycles of FOLFOX (oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every second weeks)
Study: NCT03467542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHIL® Liquid Embolic System
Description: The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
Study: NCT02733848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creon
Description: Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.~Formulations come in different fixed dose combinations as follows:~Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units~Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units~Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units~Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units~Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
Study: NCT01830595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Lactoferrin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04233268

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Pathogen Detection
Description: Rapid assays for pathogen detection on bronchoalveolar lavage fluid
Study: NCT02733848

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
Study: NCT01811641

Intervention type: OTHER
Intervention: season, dietary intake
Study: NCT02014311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTA+CTP guided treatment strategy
Description: CTA+CTP guided treatment strategy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTA guided treatment strategy
Description: CTA guided treatment strategy
Study: NCT03875326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mA HD-tDCS
Description: Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 mA HD-tDCS
Description: Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 mA HD-tDCS
Description: Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
Study: NCT01172925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaler
Study: NCT04341805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PrevOmega
Description: The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of AGHO depending on the randomization performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline
Description: The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of SSF depending on the randomization performed.
Study: NCT02324504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C3 Wave ECG-based PICC Tip Confirmation System
Description: The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will be connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
Study: NCT03588533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: * Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: - Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
Study: NCT00216619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
Study: NCT03588533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: - Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks
Study: NCT03244527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA supplement
Description: Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BCAA supplement
Description: Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise
Description: The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
Study: NCT05630274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study: NCT03748680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensified Follow-up Schedule
Description: Close monitoring with Imaging during follow-up Patients included in this trial will undergo intensified follow-up with CT-chest and abdomen every four months after surgery for the first 2 years, then every 6 months for 1 years and finally once yearly for the last 2 years up to 5 years follow-up is completed.
Study: NCT03121599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic (18F-FLT PET/CT)
Description: The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
Study: NCT05630274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT04824404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT-Buprenorphine + Recovery Coach
Description: This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professionalCBT4CBT-Buprenorphine is an 8-session (module) system for teaching a wide range of CBT skills (understanding and changing patterns of substance use; coping with craving; refusing offers of drugs and alcohol; problem-solving skills; identifying and changing thoughts about drugs and alcohol; and improving decision-making skills)
Study: NCT02216123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine Placebo
Description: Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: One of two formulations of commercially available generic chloroquine may be utilized in this study:~1. tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~2. tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: One of two formulations of commercially available generic chloroquine may be utilized in this study:~1. tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~2. tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Placebo
Description: Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
Study: NCT05560672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord blood mononuclear cells
Description: Intravenous infusion of cord blood mononuclear cells